BIOMAT Database Logo BIOMAT Database Logo

Development of monoclonal antibodies for the selective isolation of human plasma apolipoprotein A-containing particles. 1995

C Calvo, and P Bustos, and J Sepulveda, and N Ulloa, and V Sepulveda
Departamento Bioquímica Clínica e Immunologiía, Facultad de Farmacia, Universidad de Concepción, Chile.

Monoclonal antibodies (MAbs) to human plasma apolipoprotein A-I (apo A-I), denoted FF9 and 6B9, and apolipoprotein A-II (apo A-II), 3F5, were developed to be used in an immunoaffinity chromatography procedure to isolate lipoprotein particles Lp A-I and Lp A-I:A-II. MAb FF9 and MAb 6B9 reacted with apo A-I and high-density lipoprotein (HDL) while MAb 3F5 was directed to apo A-II and HDL. The apparent affinity constant (Kapp) for apo A-I of the MAb FF9 was higher (2 x 10(7) M-1) than that of 6B9 (5 x 10(6) M-1). MAb 3F5 recognized the apo A-II with a Kapp value of 1 x 10(9) M-1. The isolated lipoparticles Lp A-I and Lp A-I:A-II will be used to standardize an immunoassay for the measurement of these apo A-I-containing lipoprotein particles in human plasma.

UI MeSH Term Description Entries
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000915 Antibody Affinity A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes. Affinity, Antibody,Antibody Avidity,Avidity, Antibody,Affinities, Antibody,Antibody Affinities,Antibody Avidities,Avidities, Antibody
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody
D016632 Apolipoprotein A-I The most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. This protein serves as an acceptor for CHOLESTEROL released from cells thus promoting efflux of cholesterol to HDL then to the LIVER for excretion from the body (reverse cholesterol transport). It also acts as a cofactor for LECITHIN CHOLESTEROL ACYLTRANSFERASE that forms CHOLESTEROL ESTERS on the HDL particles. Mutations of this gene APOA1 cause HDL deficiency, such as in FAMILIAL ALPHA LIPOPROTEIN DEFICIENCY DISEASE and in some patients with TANGIER DISEASE. Apo A-I,Apo A-1,Apo A-I Isoproteins,Apo A1,Apo AI,ApoA-1,ApoA-I,Apolipoprotein A-1,Apolipoprotein A-I Isoprotein-2,Apolipoprotein A-I Isoprotein-4,Apolipoprotein A-I Isoproteins,Apolipoprotein A1,Apolipoprotein AI,Apolipoprotein AI Propeptide,Pro-Apo A-I,Pro-Apolipoprotein A-I,Proapolipoprotein AI,Apo A I Isoproteins,Apolipoprotein A 1,Apolipoprotein A I,Apolipoprotein A I Isoprotein 2,Apolipoprotein A I Isoprotein 4,Apolipoprotein A I Isoproteins,Pro Apo A I,Pro Apolipoprotein A I
D016633 Apolipoprotein A-II The second most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. It has a high lipid affinity and is known to displace APOLIPOPROTEIN A-I from HDL particles and generates a stable HDL complex. ApoA-II can modulate the activation of LECITHIN CHOLESTEROL ACYLTRANSFERASE in the presence of APOLIPOPROTEIN A-I, thus affecting HDL metabolism. Apo A-II,Apo A-2,Apo A-II Isoproteins,Apo A2,Apo AII,ApoA-2,ApoA-II,Apolipoprotein A-2,Apolipoprotein A-II Isoproteins,Apolipoprotein A2,Apolipoprotein AII,Pro-Apo A-II,Pro-Apolipoprotein A-II,Proapolipoprotein A-II,Apo A II Isoproteins,Apolipoprotein A 2,Apolipoprotein A II,Apolipoprotein A II Isoproteins,Pro Apo A II,Pro Apolipoprotein A II,Proapolipoprotein A II
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

C Calvo, and P Bustos, and J Sepulveda, and N Ulloa, and V Sepulveda
Selective isolation of human plasma low-density lipoprotein particles containing apolipoproteins B and E by use of a monoclonal antibody to apolipoprotein B.
May 1987, Biochemistry,
C Calvo, and P Bustos, and J Sepulveda, and N Ulloa, and V Sepulveda
Development of a radial immunodiffusion technique employing monoclonal antibodies for apolipoprotein B determination in human plasma.
April 1985, Clinica chimica acta; international journal of clinical chemistry,
C Calvo, and P Bustos, and J Sepulveda, and N Ulloa, and V Sepulveda
Characterization of a monoclonal antibody that binds equally to all apolipoprotein and lipoprotein forms of human plasma apolipoprotein B. II. Isolation of apolipoprotein B-containing lipoproteins from human plasma.
March 1986, Biochimica et biophysica acta,
C Calvo, and P Bustos, and J Sepulveda, and N Ulloa, and V Sepulveda
Immunoprecipitation of apolipoprotein B-containing lipoproteins for isolation of HDL particles.
September 2014, Clinica chimica acta; international journal of clinical chemistry,
C Calvo, and P Bustos, and J Sepulveda, and N Ulloa, and V Sepulveda
Very small apolipoprotein A-I-containing particles from human plasma: isolation and quantification by high-performance size-exclusion chromatography.
February 2000, Clinical chemistry,
C Calvo, and P Bustos, and J Sepulveda, and N Ulloa, and V Sepulveda
Apolipoprotein D and cross-reacting human plasma apolipoproteins identified using monoclonal antibodies.
June 1986, The Journal of biological chemistry,
C Calvo, and P Bustos, and J Sepulveda, and N Ulloa, and V Sepulveda
Isolation and characterization of apolipoprotein B48-containing lipoproteins with a monoclonal antibody against apolipoprotein B48.
January 2009, Journal of atherosclerosis and thrombosis,
C Calvo, and P Bustos, and J Sepulveda, and N Ulloa, and V Sepulveda
Protein heterogeneity of lipoprotein particles containing apolipoprotein A-I without apolipoprotein A-II and apolipoprotein A-I with apolipoprotein A-II isolated from human plasma.
December 1988, Journal of lipid research,
C Calvo, and P Bustos, and J Sepulveda, and N Ulloa, and V Sepulveda
Quantitative measurement of lipoprotein particles containing both apolipoprotein AIV and apolipoprotein B in human plasma by a noncompetitive ELISA.
June 2002, Clinical chemistry,
C Calvo, and P Bustos, and J Sepulveda, and N Ulloa, and V Sepulveda
Characterization of monoclonal antibodies against human apolipoprotein E.
July 1981, The Journal of clinical investigation,
Copied contents to your clipboard!